Clinical efficacy of empiric antibiotic therapy in Chinese patients with cirrhosis and bacterial infections: A multicenter study
PLOS One · 2026
DOI: 10.1371/journal.pone.0357491 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS One, 2026. Verfasst von Liqin Sheng und 40 weiteren Autor:innen. Beteiligte Einrichtung: Haiyan People's Hospital, Jiaxing, Zhejiang, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Bacterial Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Major Science and Technology Projects of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background & Aims Bacterial and fungal infections are major drivers of acute decompensation and acute-on-chronic liver failure (ACLF) in cirrhosis, but real-world data on the effectiveness of empiric antibiotic therapy in China are scarce. We evaluated clinical response to empiric antibiotics, identified predictors of non-response, and assessed the impact of response and secondary infection on short-term outcomes in Chinese patients with cirrhosis. Approach & Results In this multicenter retrospective cohort from 24 tertiary centers, 1,401 adults with cirrhosis and bacterial or fungal infections were included. Clinical response to first-line empiric therapy occurred in 913 patients (65%). Non-responders had higher MELD/MELD-Na scores, more organ failures and ACLF, and more intense systemic inflammation. In multivariable models, greater ACLF grade 2–3, systemic inflammatory response syndrome, higher neutrophil-to-lymphocyte ratio, C-reactive protein, bilirubin, culture positivity, and lower albumin and mean arterial pressure independently predicted non-response. Non-response was independently associated with 28-day and 90-day mortality (HR 4.20 and 3.16, respectively), with consistent findings in time-dependent and center-clustered sensitivity analyses. Secondary infection developed in 7.0% of patients, was four-fold more frequent in non-responders (13.9% vs 3.3%), and nearly doubled 90-day mortality, whereas microbiological features at secondary infection did not clearly distinguish second-course responders from non-responders. Comparative analyses revealed substantial center-to-center and China-global differences in etiology, infection profile, and multidrug-resistant (MDR) burden. Conclusions In Chinese patients with cirrhosis, lack of early clinical response to empiric antibiotics independently predicts short-term mortality and is associated with a higher risk of clinically distinct secondary infection. Our findings support risk-adapted, locally informed empiric strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Haiyan People's Hospital, Jiaxing, Zhejiang, China.
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zheji…
- Hangzhou First People's Hospital Tonglu Hospital, Hangzhou, China.
- Department of Infectious Diseases, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
- Department of Infectious Diseases, Affiliated Hospital of Jiaxing University/The First Hospital of Jiaxing, Jiaxing, Zhejiang, China.
- Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Förderung
- National Major Science and Technology Projects of China
- National Natural Science Foundation of China
Zitieren
APA
Sheng, L., Zhang, X., Weng, H., Deng, Q., Deng, M., Wu, X., Huang, Z., Liu, S., Wu, R., Ma, C., Xu, Y., Zhong, J., Yang, J., Wu, Y., Shen, H., Ding, F., Wang, F., Zhai, X., Peng, C., …, & Yu, X. (2026). Clinical efficacy of empiric antibiotic therapy in Chinese patients with cirrhosis and bacterial infections: A multicenter study. PLOS One. https://doi.org/10.1371/journal.pone.0357491
Vancouver
Sheng L, Zhang X, Weng H, Deng Q, Deng M, Wu X, et al. Clinical efficacy of empiric antibiotic therapy in Chinese patients with cirrhosis and bacterial infections: A multicenter study. PLOS One. 2026. doi:10.1371/journal.pone.0357491
BibTeX
@article{Sheng2026,
author = {Sheng, Liqin and Zhang, Xiuding and Weng, Haoda and Deng, Qinzhi and Deng, Min and Wu, Xuwei and Huang, Zuxiong and Liu, Shourong and Wu, Rui and Ma, Chunlian and Xu, Yao and Zhong, Jianfeng and Yang, Jie and Wu, Yinxia and Shen, Huajiang and Ding, Feng and Wang, Fang and Zhai, Xuezhen and Peng, Chunxian and Ren, Haotang and Jin, Jie and Xu, Xiangfei and Li, Xiaofei and Ye, Xiaoting and Qian, Guoqing and Sun, Shuilin and Yao, Xuebing and Miao, Haifeng and Xiao, Qianggu and Ye, Shaoheng and Zhang, Qing and Xu, Xinyi and Xu, Xianbin and Yu, Yue and Tu, Huilan and Zhang, Xinrong and Huang, Rui and Yang, Qiao and Sheng, Jifang and Shi, Yu and Yu, Xia},
title = {Clinical efficacy of empiric antibiotic therapy in Chinese patients with cirrhosis and bacterial infections: A multicenter study},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0357491}
}
EUVIMED